Hansa Biopharma AB · OMXSTO:HNSA

Hansa Biopharma AB — Needham Annual Healthcare Conference 2022

19 slides from Hansa Biopharma AB's conference presentation, Apr 13, 2022

  1. Slide 1: Investor Presentation

    Investor Presentation Needham Annual Healthcare Conference April 13, 2022 Søren Tulstrup President & CEO …at Hansa Biopharma we envision a world where all patients with rare immunologic diseases can lead long and healthy lives...

  2. Slide 2: Forward-looking statements

    Forward-looking statements This presentation may contain certain forward-looking statements and forecasts based on our current expectations and beliefs regarding future events and are subject to significant uncertainties and risks since they relate to events and depend on circumstances that will occ

  3. Slide 3: Hansa Biopharma today

    Hansa Biopharma today Successful track record... A validated Idefirix® is our first Broad pipeline in Strong momentum... technology approved drug in transplantation and Europe* autoimmunity Promising future... VALIDATION ACROSS THREE AREAS EUROPE KIDNEY PROGRAMS IN CLINICAL TRANSPLANTS DEVELOPMENT A

  4. Slide 4: Many milestones achieved during the last 15 months

    Many milestones achieved during the last 15 months First patient enrolled in Pricing and Marketing the U.S. pivotal reimbursement authorization in randomized controlled achieved for Idefirix® Israel for Idefirix® study ”ConfIdeS” in highly in Germany (imlifidase) Healthcare Technology sensitized kid

  5. Slide 5: Imlifidase: a novel approach to eliminate pathogenic IgG

    Imlifidase A novel approach to eliminate pathogenic IgG Origins from a bacteria A unique IgG antibody-cleaving enzyme Inactivates IgG in 2-6 hours Streptococcus pyogenes • Species of Gram-positive, spherical • Interacts with Fc-part of IgG with extremely high specificity • Rapid onset of action that

  6. Slide 6: Potential indication universe

    Gene therapy pre-treatment Potential indication universe (partnership opportunity) Transplantation and post transplantation (Own commercial infrastructure in EU/US) … … … Limb- Transplantation and Pompe post transplantation Girdle … Lung Heart disease (LGMD) Other areas Lung Duchenne First generatio

  7. Slide 7: Our Business model

    Our Business model Leveraging our technology platform to develop new therapies targeting rare diseases with unmet medical need across a range of indications Growth engine Value chain Commercialization Leveraging our We are controlling Build-up of Indications Multiple proprietary antibody the full va

  8. Slide 8: Idefirix (imlifidase) has received conditional approval in the European Union

    Idefirix® (imlifidase) has received conditional approval in the European Union Low Higher complexity complexity transplants transplants ~70% of patients1,2 15-20% of patients1,2 10-15% of patients1,2 Non or less sensitized Moderately sensitized Highly sensitized (cPRA < 20%) (20% < cPRA < 80%) (cPRA

  9. Slide 9: The kidney transplantation landscape in Europe and the U.S.

    The kidney transplantation landscape in Europe and the U.S. Up to 15% of patients waiting for a new kidney are highly sensitized European transplantation rates were negatively affected by COVID-19 Breakdown of the kidney transplant U.S. annual transplantations 5Y avg 22 083 Total YoY waitlist in U.S

  10. Slide 10: Commercial sales uptake

    Our center focused and sequenced launch process (”S”-shaped launch curve) will help build the foundation for Idefirix® to become a new Standard of Care in transplantation Idefirix® is the first and only approved treatment in Europe for desensitization treatment of highly sensitized kidney transplant

  11. Slide 11: Ongoing market access processes

    Ongoing market access processes EU4+UK represent ~15,000 annual kidney transplants1 United Kingdom 3,649 Transplants1 Pricing and reimbursement obtained in France (early access), Germany, Sweden, Netherlands as well as Finland and Greece on a hospital basis; 10 clinics qualified as clinically ready

  12. Slide 12: U.S. ConfIdeS study: First patient enrolled Dec'21; BLA submission expected H1 2024

    U.S. ConfIdeS study: First patient enrolled Dec’21; BLA submission expected H1 2024 U.S. trial design 64 highly sensitized kidney patients with the highest unmet medical need Timeline • Patients with a cPRA score of ≥99.9% will be enrolled • First patients enrolled at Columbia University, NYC First

  13. Slide 13: Broad clinical pipeline in transplantation and auto-immune diseases

    Broad clinical pipeline in transplantation and auto-immune diseases Candidate/ Research/ Marketing Program Indication Preclinical Phase 1 Phase 2 Phase 3 Authorization Marketed Next Anticipated Milestone EU: Additional agreements around EU: Kidney transplantation in highly sensitized patients 1,2 *)

  14. Slide 14: Our unique antibody cleaving enzyme technology may have relevance across a range of indications

    Our unique antibody cleaving enzyme technology may have relevance across a range of indications Targeting rare IgG mediated diseases Expanding our commercial franchises Regulatory approval (conditional) Clinical development Partnership (preclinical development) Preclinical development Anti-GBM paves

  15. Slide 15: Imlifidase treatment of anti-GBM disease highlighted in JASN

    Imlifidase treatment of anti-GBM disease highlighted in JASN (Journal of American Society of Nephrology)1 Encouraging phase 2 data marks an important milestone for Hansa Biopharma’s IgG antibody cleaving technology platform outside transplantation The JASN publication recognises the potential in 10

  16. Slide 16: Collaboration with AskBio to evaluate imlifidase in gene therapy targeting Pompe disease

    Collaboration with AskBio to evaluate imlifidase in gene therapy targeting Pompe disease Feasibility program to evaluate imlifidase as pre-treatment ahead of gene therapy in Pompe disease for patients with pre-existing neutralizing antibodies (NAbs) to adeno-associated virus (AAV) Fully owned subsid

  17. Slide 17: Upcoming milestones

    Upcoming milestones Milestones subject to potential COVID-19 impact Kidney transplantation Long-term follow- AMR Anti-GBM U.S. complete GBS Phase 2 up data 5-years Kidney Phase 2 complete Initiation of enrollment first data read out* out in kidney transplantation enrollment Phase 3 study (H2 2022) (

  18. Slide 18: Hansa Biopharma

    MZ HANSAT BIOPHARMA

  19. Slide 19: Corporate Contacts

    Corporate Contacts Visit our web site Investor Relations and www.hansabiopharma.com Corporate Communications Calendar and events April 21 2022 Interim Report for January-March 2022 Klaus Sindahl April 21 2022 Kempen Life Sciences Conference 2022, Amsterdam Head of Investor Relations April 27 2022 Re

Hansa Biopharma — Needham Annual Healthcare Conference 2022 on 6ix